What is a multidisciplinary tumor board and should my Triple-Negative Breast Cancer case be presented

Understanding Multidisciplinary Tumor Boards for Triple-Negative Breast Cancer

What Is a Multidisciplinary Tumor Board?

A multidisciplinary tumor board (also called a molecular tumor board or tumor conference) is an interdisciplinary team of cancer experts from different specialties who meet together to review and discuss individual patient cases. The team typically includes:

• Medical oncologists (chemotherapy specialists)
• Surgical oncologists (cancer surgeons)
• Radiation oncologists (radiation therapy specialists)
• Pathologists (tissue/lab specialists)
• Radiologists (imaging specialists)
• Nurses and other specialists relevant to your cancer type

According to the Cancer Patient Lab webinars on personalized cancer care, a tumor board functions as an interdisciplinary team of experts in the disease field who collaborate to develop treatment recommendations tailored to individual patients.

How Tumor Boards Work

The team reviews your:

• Pathology report (what type of cancer it is)
• Imaging studies (scans showing where cancer is located)
• Molecular/genetic testing results (if available)
• Medical history and overall health status
• Treatment goals and preferences

Together, they discuss the best treatment approach for YOUR specific situation rather than applying a one-size-fits-all approach.

Should Your Triple-Negative Breast Cancer Case Be Presented?

Yes, absolutely. Here's why tumor board review is particularly valuable for triple-negative breast cancer (TNBC):

Why TNBC Benefits from Tumor Board Discussion

Triple-negative breast cancer is more complex because it lacks three common treatment targets (estrogen receptor, progesterone receptor, and HER2), which means:

1. Fewer standard targeted therapy options - Your oncologist needs to think creatively about treatment approaches
2. Immunotherapy may be relevant - TNBC often responds well to immunotherapy, but determining which patients benefit requires careful analysis
3. Chemotherapy selection matters - Different chemotherapy combinations may work better for different patients
4. Emerging biomarkers - Testing for markers like PD-L1, tumor mutational burden (TMB), or BRCA mutations can guide treatment decisions

According to NCCN Guidelines for breast cancer, multidisciplinary evaluation is recommended for treatment planning, particularly for complex cases like triple-negative disease.

Important Limitation: Tumor Board Concordance

Here's something important to understand: tumor boards don't always agree. Research cited in the Cancer Patient Lab webinars on treatment matching shows that when the same molecular diagnostic results are sent to two different tumor boards, concordance (agreement) on treatment recommendations is only 44-63%.

This means:

• Different experts may interpret the same data differently
• There may be legitimate disagreement about the best approach
• Your oncologist's clinical judgment remains crucial

Questions to Ask Your Oncology Team

To ensure your case gets appropriate tumor board review:

1. "Will my case be presented to a multidisciplinary tumor board?" - Some institutions do this routinely; others do it on request.

2. "What specific information will be reviewed?" - Ask if they'll include any molecular testing results (genomic sequencing, immunotherapy biomarkers, etc.)

3. "If I have molecular testing done, will that be incorporated into the tumor board discussion?" - This is especially relevant for TNBC, where biomarkers can guide immunotherapy decisions.

4. "How will the tumor board's recommendations be communicated to me?" - You should understand what they discussed and why certain treatments are recommended.

5. "Can I request a second opinion if I want one?" - Given the variability in recommendations, getting another expert's perspective is reasonable.

Molecular Testing and Tumor Boards

For triple-negative breast cancer specifically, consider asking about:

• Genomic sequencing (whole exome or targeted panel) to identify actionable mutations
• PD-L1 testing - helps predict immunotherapy response
• Tumor mutational burden (TMB) - another immunotherapy predictor
• BRCA testing - if not already done, as this affects treatment options

According to the Cancer Patient Lab webinars on personalized treatment matching, comprehensive molecular profiling can help identify treatment options beyond standard chemotherapy, which is particularly important for TNBC where options are more limited.

Bottom Line

Your triple-negative breast cancer case should be presented to a multidisciplinary tumor board because:

• TNBC is complex and benefits from multiple expert perspectives
• Molecular testing results can guide personalized treatment decisions
• A coordinated team approach improves treatment planning
• You deserve input from specialists across different disciplines

This is standard of care for breast cancer treatment planning and is especially valuable for triple-negative disease.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.